Amgen Struggles To Spark Enbrel Growth, Faces Increased Competition
Executive Summary
Amgen's strategies for reviving growth in Enbrel (etanercept) are not producing the anticipated results, as the TNF inhibitor has delivered lackluster sales for several consecutive quarters
You may also be interested in...
Mid-Cap Biotechs Rise In ’06; Small Firms Face “Burden” Of New Products
Disappointing product launches by CV Therapeutics and NitroMed underscore the challenges that small manufacturers face in trying to successfully bring new products to market
Mid-Cap Biotechs Rise In ’06; Small Firms Face “Burden” Of New Products
Disappointing product launches by CV Therapeutics and NitroMed underscore the challenges that small manufacturers face in trying to successfully bring new products to market
Amgen To Re-Launch AMG 706 Phase II Enrollment, Phase III Still Delayed
Amgen will re-launch enrollment of head-to-head Phase II studies for its oncologic AMG 706 after concerns were raised about the potential development of cholecystitis, although the Phase III trials remain indefinitely delayed